Investment will enable pHion to progress its lead program into the clinic
Drug Discovery World
JUNE 7, 2023
The additional investment will support growth of the company’s proprietary RALA platform with an immediate focus on the advancement of pHion’s lead project, PTX_V1, into clinical trials in the first half of 2024. PTX_V1 is a first-in-class therapeutic vaccine for the treatment of human papilloma virus (HPV)-related cancers.
Let's personalize your content